Comparison of granisetron and palonosetron in triplet anti-emetic prophylaxis in non-small cell lung cancer patients receiving cisplatin-based highly emetogenic chemotherapy
Rattachement africain : tr. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
IntroductionWe compared the efficacy of first-generation granisetron and second-generation palonosetron in triplet anti-emetic prophylaxis in patients with non-small cell lung cancer (NSCLC) receiving cisplatin-based high emetogenic chemotherapy (HEC).MethodsThis prospective, multicenter, non-randomized, observational study was conducted between June 2018 and December 2021. Patients diagnosed with NSCLC who received triplet anti-emetic prophylactic treatment with aprepitant and dexamethasone plus granisetron or palonosetron before the first cycle of chemotherapy were included in the study. At the end of the first week after chemotherapy, the emesis scale was applied to the patients during the outpatient control. The primary endpoint was complete response (CR) and total control (TC).ResultsOne hundred twenty-one patients were included in the study. Sixty-one patients were in the granisetron group and 60 patients were in the palonosetron group. CR was higher with granisetron in the acute phase (70.5% vs. 58.3%, p = 0.16; respectively) and higher with palonosetron in the delayed phase (61.7% vs. 55.7%, p = 0.5; respectively), although not statistically significant. The TC rates were also not significantly different between the groups (54.1% vs.57.6%, p = 0.69).ConclusionsThere was no significant difference between granisetron and palonosetron in both acute and delayed control of emesis in NSCLC patients receiving cisplatin-based HEC.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Comparison of granisetron and palonosetron in triplet anti-emetic prophylaxis in non-small cell lung cancer patients receiving cisplatin-based highly emetogenic chemotherapy
- Date Crossref
- 28/08/2024
- Éditeur
- SAGE Publications
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Necmettin Erbakan University Department of Medical Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Alanya University pays non établi dans la noticeUniversité ou école supérieure
-
Alanya Alaaddin Keykubat Üniversitesi pays non établi dans la noticeUniversité ou école supérieure
-
Karabük University Department of Medical Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Canakkale Onsekiz Mart Universitesi Tip Fakultesi Hastanesi pays non établi dans la noticeÉtablissement de santé
-
Alanya Alaaddin Keykubat University Department of Medical Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Çanakkale 18 March University Faculty of Medicine Department of Medical Oncology pays non établi dans la noticeUniversité ou école supérieure
Department of Medical Oncology — Necmettin Erbakan University, Alanya University et Alanya Alaaddin Keykubat Üniversitesi, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.